^
    8d
    Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, University of Washington
    New P2 trial
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg)
    29d
    The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia. (PubMed, Br J Haematol)
    We evaluated the tolerability and efficacy of pegylated interferon alfa-2B (peg-IFNα; PegIntron, MSD) combined with nilotinib in the Australasian Leukaemia and Lymphoma Group CML11 (Pinnacle) study. CML11 demonstrated that peg-IFNα with nilotinib leads to high rates of molecular response, with tolerability similar to prior studies. Trial registration ANZCTRN12612000851864.
    P2 data • Journal
    |
    ABL1 (ABL proto-oncogene 1) • IFNA1 (Interferon Alpha 1)
    |
    Tasigna (nilotinib) • ViraferonPeg (peginterferon-α-2b)
    2ms
    TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=52, Recruiting, University of California, Davis | Not yet recruiting --> Recruiting | Trial completion date: Dec 2030 --> Feb 2030
    Enrollment open • Trial completion date
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    2ms
    Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions. (PubMed, Cancers (Basel))
    Nadofaragene firadenovec, a recombinant adenovirus delivering interferon alpha-2b (IFNα2b), is the first FDA-approved gene therapy for BCG-unresponsive NMIBC with carcinoma in situ (CIS)...Cretostimogene grenadenorepvec (CG0070), an oncolytic vector, demonstrated a 47% 6-month CR rate in a phase II study (NCT02365818). Detalimogene voraplasmid (EG-70), a nonviral gene therapy, demonstrated a 47% 6-month CR in a phase I/II study (NCT04752722). Future advances are likely to focus on patient selection, novel vectors, and combination strategies to improve treatment outcomes. Gene therapy represents a significant addition to the bladder cancer treatment landscape by offering bladder-sparing alternatives where conventional therapies are limited.
    Review • Journal
    |
    IFNA1 (Interferon Alpha 1)
    |
    Adstiladrin (nadofaragene firadenovec-vncg) • cretostimogene grenadenorepvec (CG0070) • detalimogene voraplasmid (EG-70)
    3ms
    iinnovate-1: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=272, Terminated, Takeda | Completed --> Terminated; Terminated by the sponsor for strategic reasons
    Trial termination
    |
    dexamethasone injection • modakafusp alfa (TAK-573)
    4ms
    EFFECTS OF TREATMENT WITH TEMSIROLIMUS VERSUS INTERFERON ALPHA ON SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA - SINGLE-CENTER REAL-WORLD EXPERIENCE. (PubMed, Acta Clin Croat)
    In conclusion, temsirolimus therapy had a significantly positive effect on survival in patients with mRCC. Patients treated with temsirolimus showed significantly longer median survival and median PFS compared to patients treated with IFN-alpha.
    Clinical • Retrospective data • Journal • Real-world evidence
    |
    IFNA1 (Interferon Alpha 1)
    |
    temsirolimus • Roferon A (recombinant interferon alfa-2a)
    4ms
    ABLE-32: Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=454, Recruiting, Ferring Pharmaceuticals | Trial completion date: Mar 2030 --> Jun 2031 | Trial primary completion date: Mar 2030 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    4ms
    PETALs: Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (clinicaltrials.gov)
    P3, N=200, Completed, Hospices Civils de Lyon | Unknown status --> Completed
    Trial completion
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Tasigna (nilotinib) • Pegasys (pegylated interferon α -2a)
    4ms
    TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=52, Not yet recruiting, University of California, Davis
    New P1 trial
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    5ms
    Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)
    P3, N=25, Active, not recruiting, Ferring Pharmaceuticals | Trial primary completion date: Oct 2025 --> Nov 2029
    Trial primary completion date
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    5ms
    ABLE-41: ADSTILADRIN Early Utilization and Outcomes in the Real World Setting (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, Ferring Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    6ms
    iinnovate-2: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Terminated, Takeda | Completed --> Terminated; Due to strategic reasons (no safety concerns).
    Trial termination
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • modakafusp alfa (TAK-573)